APPLICANT'S ART CITATION (Use several sheets if necessary)	Application Not Yet Known	OFGS File No. P/1259-637 DIV
	Applicant Fernand Labrie	
	Filing Date Herewith	Group Art Unit --

U.S. PATENT DOCUMENTS

Examiner Initial	Document Number	Date	Name	Class	Sub-class	Filing Date If Appropriate
SRC	5,577,692	7/1998	Labrie			
	5,843,981	12/1/98	Clay et al.			
	3,742,951	7/3/73	Zaffaroni			
	3,797,494	3/19/74	Zaffaroni			
	4,568,343	2/4/86	Leeper			
	4,626,246	11/25/86	Nuwayser			
	4,661,105	5/19/87	Andriola			
	5,062,841	11/12/91	Berner			
	5,071,644	12/10/91	Viegas			
	5,071,657	12/10/91	Oloff			
	5,134,308	8/4/92	Bannon			
	5,154,924	10/13/92	Govil			
	5,162,207	11/10/92	Whitson-Fischman			
	5,360,610	11/1/94	Sim			
	5,362,720	11/8/94	Labrie			
	5,389,640	2/14/95	Labroo			
	5,391,556	2/21/95	Cullinan			
	5,393,755	2/28/95	Black			
	5,407,947	4/18/95	Bryant			
	5,494,947	2/6/96	Fontana			
	5,523,332	6/4/96	Bryant			
	5,550,170	8/27/96	Labrie			
	5,562,923	10/22/96	Dodge			
	5,731,343	3/24/98	Cullinan			
	5,773,474	6/30/98	McClean, et al.			
SRC	5,863,961	1/19/99	McLean, et al.			

Examiner SRC Date Considered 7/31/03

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.

APPLICANT'S ART CITATION (Use several sheets if necessary)	Application Not Yet Known	OFGS File No. P/1259-637 DIV
	Applicant Fernand Labrie	
	Filing Date Herewith	Group Art Unit --

U.S. PATENT DOCUMENTS

Examiner Initial	Document Number	Date	Name	Class	Sub-class	Filing Date If Appropriate
SRY	5 9 4 8 7 7 5	9/7/99	Koko, et al.			
	5 9 7 7 0 9 3	11/2/99	Palkowitz			
	5 9 9 8 4 4 1	12/7/99	Palkowitz			
SRY	6 0 6 0 5 0 3	5/9/00	Labrie			

FOREIGN PATENT DOCUMENTS

	Document Number	Date	Country	Class	Sub-class	Translation Yes	Translation No
SRY	WO 7 8 1 5 5 5	7/2/97	Europe				
	WO 93 1 0 7 4 1	6/10/93	PCT				
	WO 99 6 3 9 7 4	12/99	PCT				
	WO 99 0 9 0 0 7	02/99	PCT				
	WO 01 0 1 9 6 9	01/01	PCT				
	06 5 9 4 2 3 A1	12/94	Europe				
	07 1 6 8 5 5 A2	12/8/95	Europe				
	2 7 9 9 8 2	8/31/88	Europe				
	3 1 0 5 4 2	4/5/89	Europe				
	6 3 5 2 5 6 4	1/25/95	Europe				
	6 5 1 9 9 8 A1	5/10/95	Europe				
	6 5 7 1 6 2	6/14/95	Europe				
	6 6 5 0 1 5 A2	8/2/95	Europe				
	6 7 4 9 0 3 A1	10/4/95	Europe				
	6 9 3 2 8 5 A2	1/24/96	Europe				
	7 0 3 2 3 1	3/27/96	Europe				
	7 1 2 6 2 8	5/22/96	Europe				
	7 2 9 9 5 5	9/4/96	Europe				
SRY	7 2 9 9 5 6	9/4/96	Europe				

Examiner SRY Date Considered 7/31/03

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP §609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.

APPLICANT'S ART CITATION
(Use several sheets if necessary)

Application Not Yet Known | OFGS File No. P/1259-637 DIV

Applicant Fernand Labrie

Filing Date Herewith | Group Art Unit --

FOREIGN PATENT DOCUMENTS

	Document Number	Date	Country	Class	Sub-class	Translation Yes	Translation No
SRC	7 9 1 5 9 0	2/19/97	Europe				
	7 9 2 6 4 0	9/3/97	Europe				
	7 9 2 6 4 2 A1	9/3/97	Europe				
	8 0 1 0 6 6 A1	10/15/97	Europe				
	8 0 2 1 8 3 A1	10/22/97	Europe				
	8 0 2 1 8 4 A1	10/22/97	Europe				
	8 3 5 8 6 7	4/15/98	Europe				
	8 3 8 4 6 4	4/29/98	Europe				
	8 4 2 6 6 1	5/20/98	Europe				
	8 7 3 9 9 2 A1	10/28/98	Europe				
	8 9 5 9 8 9 A1	2/10/99	Europe				
	9 4 1 6 7 0 9	8/4/94	WIPO				
	9 6 0 7 4 0 2	3/14/96	WIPO				
	9 6 0 9 0 4 0	3/28/96	WIPO				
	9 6 1 6 6 4 6	6/6/96	WIPO				
	9 6 2 1 6 5 6	7/18/96	WIPO				
	9 6 2 6 2 0 1	8/29/96	WIPO				
	9 7 0 4 7 6 3	2/13/97	WIPO				
	9 7 2 5 0 3 4	7/17/97	WIPO				
	9 7 2 5 0 3 5	7/17/97	WIPO				
	9 7 2 5 0 3 6	7/17/97	WIPO				
	9 7 2 5 0 3 7	7/17/97	WIPO				
	9 7 2 5 0 3 8	7/17/97	WIPO				
SRC	9 7 3 1 6 4 0	9/4/97	WIPO				

Examiner SRC | Date Considered 7/31/03

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.

APPLICANT'S ART CITATION (Use several sheets if necessary)	Application Not Yet Known	OFGS File No. P/1259-637 DIV
	Applicant Fernand Labrie	
	Filing Date Herewith	Group Art Unit --

FOREIGN PATENT DOCUMENTS

	Document Number	Date	Country	Class	Sub-class	Translation Yes	Translation No
SEQ	9 7 3 2 8 3 7	7/17/97	WIPO				
	9 7 3 2 8 3 7	7/17/97	WIPO				
	9 8 4 5 2 8 7	10/15/98	WIPO				
	9 8 5 7 9 2 2	12/23/98	WIPO				
	9 8 4 9 8 9 6	11/12/98	WIPO				
	9 9 6 5 3 0 9	12/23/99	WIPO				
	0 0 7 4 6 8 4	12/14/00	WIPO				
	WO 99 5 9 5 8 1	11/25/01	WIPO				
	10 0 3 6 3 4 7	1998	Japan				X
	2 1 8 5 1 8 7	7/15/87	England				
SEQ	2 3 0 3 6 2 8	2/26/97	England				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

SEQ 1	Ammann P., Bourrin S., Bonjour J.-P., Brunner F., Meyer J.-M. and Rizzoli R., The New Selective Estrogen Receptor Modulator MDL 103,323 Increases Bone Mineral Density and Bone Strength in Adult Ovariectomized Rats, Osteoporosis Int.10, 369-276, 1999.
2	Avioli L.V., SERM Drugs for the Prevention of Osteoporosis, TEM 10(8), 317-319, 1999.
3	Barrett-Connor, E. (1993), Estrogen and estrogen-progestogen replacement therapy and cardiovascular diseases. Am. J. Med., 95 (Suppl. 5A): 40S-43S.
4	Barrett-Connor E., Cox D.A., and Anderson P.W., The Potential of SERM's for Reducing the Risk of Coronary Heart Disease TEM 10(8), 320-324, 1999
5	Black, L.J., Sato, M., Rowley, E.R., Magee, D.E., Bekele, A., Williams, D.C., Cullinan, G.J.,Bendele, R., Kauffman, R.F., Bensch, W.R., Frolik, C.A., Termine, J.D., Bryant, H.U.(1994), Raloxifene (LY 139481 HC1) prevents bone loss and reduces serum cholesterol without causing uterine hypertrophy in ovariectomized rats. J. Clin. Invest., 93: 63-69
SEQ 6	Boorman, G.A. et al.: Pathology of the Fisher Rat. Reference and Atlas, in San Diego, Academic Press, pp 433, 1990.

Examiner SEQ	Date Considered 7/31/03

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.

APPLICANT'S ART CITATION (Use several sheets if necessary)	Application Not Yet Known	OFGS File No. P/1259-637 DIV
	Applicant Fernand Labrie	
	Filing Date Herewith	Group Art Unit --

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

SEF	7	Bruning, P.F., Bonfrer, J.M.G., Hart, A.A.M., de Jong-Bakker, M., Linders, D., von Loon, J., Nooyen, W.J. (1988), Tamoxifen, serum lipoproteins and cardiovascular risk. Br. J. Cancer 58: 497-499.
	8	Cardy, R.H. (1991), Sexual dimorphism of the normal rat mammary gland. Vet. Pathol.,28: 139-145.
	9	Colditz, G.A. et al.: The use of estrogens and progestins and the risk of breast cancer in postmenopausal women. N Engl J Med. 332: 1589-1593, 1995
	10	Couillard, S., Gutman, M., Labrie, C., Belanger A., Candas, B., Labrie, F.: Comparison of the effects of the antiestrogens EM-800 and Taximofen on the growth of human breast ZR-75-1 cancer xenografts in nude mice. Cancer Res, 58: 60-64, 1998a.
	11	Couillard, S., Gutman, M., Labrie, C., Labrie, F.: Effect of combined treatment using radiotherapy and the antiestrogen EM-800 on AR-75-1 human mammary carcinoma growth in nude mice. Proc. 89th American Association for Cancer Research, New Orleans, LA, March 28 - April 1, 383, 1998b.
	12	Couillard, S., Labrie, C., Belanger, A., Candas, B., Pouliot, F., Labrie, F.: Effect of dehydroepiandrosterone and the antiestrogen EM-800 on the growth of human ZR-75-1breast cancer xenografts. J. Natl Cancer Inst, 90: 772-778, 1998c
	13	Couillard, S., Labrie, C., Gauthier, S., Merand, Y., Singh, S.M., Candas, B., Labrie F.:Long-term inhibitory effect of the orally active and pure antiestrogen EM-800 on the growth of human breast cancer xenografts in nude mice. Int J Cancer, 85:3: 424-429, 2000
	14	Cummings, S.R.: Evaluating the benefits and risks of postmenopausal hormonal therapy. Am J Med. 91 (Suppl.5B), 14S-18S, 1991.
	15	Curtis, M.G.: Selective estrogen receptor modulators: a controversial approach for managing postmenopausal health. J Womens Health, 8: 321-33, 1999.
	16	Davies, G.C., Huster, W.J., Lu, Y., Plouffe, L., Jr, Lakshmanan, M.: Adverse events reported by postmenopausal women in controlled trials with raloxifene. Obstet Gynecol,93: 55-65, 1999.
	17	Dauvois, S., Li, S., Martel, C., Labrie, F. (1989), ~hibitory effect of androgens on DMBA induced mammary carcinoma in the rat. Breast Cancer Res. Treatm., 14: 299-306
	18	Dauvois, S., Spinola, P.G., Labrie, F. (1989), Additive inhibitory effects of bromocriptine (CB-154) and medroxyprogesterone acetate (MPA) on dimethylbenz(a)anthracene (DMBA)-induced mammary tumors in the rat. Eur. J. Cancer Clin. Oncol., 25: 891-897.
SEF	19	Dauvois, S., Geng, C.S., Levesque, C., Merand, Y., Labrie, F. (1991), Additive inhibitory effects of an androgen and the antiestrogen EM-170 on estradiol-stimulated growth of human ZR-75-1 breast tumors in athymic mice. Cancer Res., 51: 3131-3135.

Examiner SEF	Date Considered 7/31/03

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.

APPLICANT'S ART CITATION (Use several sheets if necessary)	Application Not Yet Known	OFGS File No. P/1259-637 DIV
	Applicant Fernand Labrie	
	Filing Date Herewith	Group Art Unit --

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

SRS	20	De Fazio, J., Meldrum, D.R., Winer, J H., Judd, H.L. (1984), Direct action of androgen on hot flushes in the human male. Maturitas, 6: 3-8.
	21	DeGregorio, M.W. and Taras, T.L., Hormone replacement therapy and breast cancer: revisiting the issues, J Am Pharm Assoc., 38, 738-46, 1998
	22	De Visser, J., Coert, A., Feenstra, H., van der Vies, J., Endocrinological Studies with (7 alpha, 17 alpha)-17-hydroxy-7-methyl-19-norpregn-5(10)-en-20-yn-3-one (Org OD 14), Arzneimittelforschung 34(9): 1010-7, 1984.
	23	Diamond, P., Cusan, L., Gomez, J.L., Belanger, A., Labrie, F. (1996), Metabolic effects of 12-month percutaneous DHEA replacement therapy in postmenopausal women. J.Endocrinol., 150: S43-S50
	24	Dippipo, V.A., Lindsay, R., Powers, C.A., (1995), Estradiol and tamoxifen interactions with thyroid hormone in the ovariectomized-thyroidectomized rat. Endocrinology, 136:1020-1033.
	25	Draper, M.W., Flowers, D.E., Huster, W.J., Neild, J.A., Harper, K., Arnaud, C. (1996), A controlled trial of raloxifene (LY139481) HCl: impact on bone turnover and serum lipid profile in healthy postmenopausal women. J.Bone Miner. Res., 11: 835-842.
	26	Foster, G.V., Zacur, H.A., Rock, J.A.: Hot flashes in postmenopausal women ameliorated by danazol. Fertil Steril, 43: 401-4, 1985.
	27	Fitzpatrick, L.A. Selective Estrogen Receptor Modulators and Phytoestrogens: New Therapies for the Postmenopausal Woman, Mayo Clin Proc. 74, 601-607, 1999
	28	Frishman, G.N.: The hot flash: pathophysiology and treatment. R I Med. 78: 132-4, 1995.
	29	Gallagher, A., Chambers, T.J., Tobias, J.H. (1993), The estrogen antagonist ICI 182780 reduces cancellous bone volume in female rats. Endocrinology, 133: 2787-2791.
	30	Genazzani, A.R. and Gambacciani, M. Hormone replacement thearapy: the perspectives for the 21st century Matutitas 32, 11-17, 1999.
	31	Goldfrank, D., Haytoglu, T., Frishman, W.H., and Mohammad, Z., Raloxifene, a New Selective Estrogen Receptor Modulator, J Clin Pharmacol 39, 767-774, 1999.
	32	Gompel, A., Jacob, D., de Chambine, S., Mimoun, M., Decroix, Y., Rostene, W., Poitout, Ph., Action des <<SERM>>, <<SAS>' (Tibolone) sur le tissu mammaire. Contracept. Fertil. Sex., 27 (5), 368-375, 1999.
	33	Gauthier, S. et al. (1997): (S)-(+)-4[7-(2,2-Dimethyl-1-oxopropoxy) - 4-methyl-2-[4-[2-(1-piperidinyl)-ethoxy]phenyl]-2H-1-benzopyran-3-yl]-phenyl] -2,2-Dimethylpropanoate(EM-800): A Highly Potent, Specific, arid Orally Active Nonsteroidal Antiestrogen. J.Med. Chem., 40: 14: 2117-2122.
SRS	34	Grese et al., Synthesis and pharmacology of conformationally restricted raloxifene analogues: highly potent selective estrogen receptor modulators. J Med Chem. 1998 Apr 9; 41(8):1272-83.

Examiner SRS	Date Considered SRS 7/31/03

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.

APPLICANT'S ART CITATION (Use several sheets if necessary)	Application Not Yet Known	OFGS File No. P/1259-637 DIV
	Applicant Fernand Labrie	
	Filing Date January 26, 2001	Group Art Unit --

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

SEC	35	Hagmeyer, K., Meyer, T.: Raloxifene: a selective estrogen receptor modulator for the prevention of osteoporosis, J Pharm Technol, 15(2): 37-45, 1999.
	36	Heaney, R.P., Draper, M.W. (1997), Raloxifen and estrogen: comparative bone remodeling kinetics. J. Clin. Endrocrinol. Metab., 82: 3425-3429.
	37	Imbeault, P. et al.: Relationship of visceral adipose tissue to metabolic risk factors for coronary heart disease: is there a contribution of subcutaneous ht cell hypertrophy?Metabolism, 48: 355-362, 1999.
	38	Jordan, V.C., Phelps, E., Lindgren, J.U. (1987), Effects of anti-estrogens on bone in castrated and intact female rats. Breast Cancer Res. Treat., 10: 31-35.
	39	Judd, H.L., Meldrum, D.R. et al.: Estrogen replacement: Indications and complications, Ann Int Med: 98: 195-205, 1983
	40	Kauffman, R.F., Brvant, H.U. (1995), Effective therapeutic management of the postmenopausal state will be a cornerstone in strategies for preserving or improving women's health in the 215' century. Selecffve estrogen receptor modulators. DN & P 8: 531-539.
	41	Ke, H.Z., Simmons, H.A., Pirie, C.M., Crawford, D.T., Thompson, D.D. (1995), Droloxifene, a new estrogen antagonist/agonist, prevents bone loss in ovariectomized rats. Endocrinology, 136: 2435-2441.
	42	Ke et al., Effects of CP-336,156, a new, nonsteroidal estrogen agonist/antagonist, on bone, serum cholesterol, uterus and body composition in rat models., Endocrinology. 1998 Apr;139(4):2068-76.
	43	Koller, C., Buri., P., (1987), Proprietes et interet pharmaceuffque des gels thermoreversibles a base de poloxamers et polyxamines. S.T.P. Pharma, 3: 115-124.
	44	Labrie, F., Li, S., Labrie, C., Levesque, C., Merand, Y. (1995), Inhibitory effect of a steroidal antiestrogen (EM-170) on estrone-stimulated growth of 7,12 dimethylbenz(a)anthracene (DMBA)-induced mammary carcinoma in the rat. Breast Cancer Res.Treat., 33: 237-244.
	45	Labrie, F., Mamond, P. Cusan, L., Gomez, J.L., Belanger, A. (1997), Effect of a 12-month DHEA replacement therapy on bone, vaginum, and endometrium in postmenopausal women. J. Clin. Endocrinol. Metab., 82: 3498-3505.
	46	Labrie, F., Labrie, C., Belanger, A., Simard, J. et al.: EM-652 (SCH 57068), a third generation serm acting as pure antiestrogen in the mammary gland and endometrium. J Steroid Biochem Molec Biol, 69: 51-84 1999.
SEC	47	Love, R.R., Newcomb, P.A., Wiebe, D.A., Surawicz, T.S., Jordan, V.C., Carbone, P.P., DeMets, D.L. (1990), Effects of tamoxifen on cardiovascular risk factors in postmenopausal patients with node-negative breast cancer. J. Natl.Cancer Inst., 82: 1327-1332

Examiner SEC	Date Considered 7/31/03

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.

APPLICANT'S ART CITATION (Use several sheets if necessary)	Application Not Yet Known	OFGS File No. P/1259-637 DIV
	Applicant Fernand Labrie	
	Filing Date Herewith	Group Art Unit --

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

SAG	48	Love, R.R., Wiebe, D.A., Newcomb, P.A., Cameron, L., Leventhal, H., Jordan, V.C., Feyzi, J., DeMets, D.L. (1991), Effects of tamoxifen on cardiovascular risk factors in postmenopausal women. Ann. Med., 115: 860-864.
	49	Lu, K.H., Chang, R.S., Kledzik, G.S. (1979), Daily patterns of ovarian and pituitary hormone secretion in old female rats just prior to the onset of estrous cycle irregularity and during chronic anovulation. 61st Annual Meeting of the Endocrine Society, p.106, Abst. No. 134.
	50	Lundeen, S.C., Carver, J.M., McKean, M.L., Winneker, R.C. (1997), Characterization of the ovariectomized rat model for the evaluation of estrogen effects on plasma cholesterol levels. Endocrinology, 138: 1552-1558.
	51	Luo, S., Labrie, C., Labrie, F.: Prevention of development of dimenthylbenz(a)anthracene(CMBA)-induced mammary carcinoma in the rat by the new nonsteroidal antiestrogen EM-800 (SCH 57050). Breast Cancer Res. Treat., 49: 1-11, 1998.
	52	Luo, S., Martel, C., Sourla, A., Gauthier, S., Merand, Y., Belanger, A., Labrie, C., Labrie F.: Comparative effects of 28-day treatment with the new antiestrogen EM-800 and tarnoxifen on estrogen-sensitive parameters in the intact mouse. Int J Cancer, 73: 381-391, 1997.
	53	Luo, S., Sourla, A., Gautier, S., Merand, Y., Labrie, C., Belanger, A., Labrie, F.: Effect of 24 week treatment with the antiestrogen EM-800 on estrogen-sensitive parameters in intact and ovariectomized mice. Endocrinology, 139: 2645-2656, 1998.
	54	Luo, S., Sourla, A., Labrie, C., Belanger, A., Labrie, F.: Combined effects of dehydroepiandrosterone and EM-800 on bone mass, serum lipids, and the development of dimethylbenz(a)anthracene (DMBA)-induced mammary carcinoma in the rat. Endocrinology, 138: 4435-4444, 1997.
	55	Maenpaa, J.U., Ala-Fossi S.L.: Toremifene in postmenopausal breast cancer. Efficacy, safety and cost. Drugs Agins, 11: 261-70, 1997.
	56	Magarian, R.A., Overacre, L.B., Singh, S., Meyer, K.L.: The Medicinal Chemistry of Nonsteroidal Antiestrogens: A Review. Curr.Med.Chem., 1994, 1:61-104.
	57	Martel, C., Labrie, C., Belanger, A., Gauthier, S., Merand, Y., Provencher, L., Li, S., Labrie, F.: Comparison of the effects of the new orally antiestrogen EM-800 with ICI 182 780 and toremifene on estrogen-sensitive parameteres in the ovariectomized mouse. Endocrinology, 139: 2486-2492, 1998.
	58	Martel, C., Sourla, A., Fournier, M., Picard, S., Li, S., Stojanovic, M., Pelletier, G., Labrie, F. (1998), Predominant androgenic component in the stimulatory effect of dehydroepiandrosterone (DHEA) on bone mineral density in the rat. J. Endocrinol., 157: 433-442.
	59	Martel et al., Binding Characteristics of Novel Nonsteroidal Antiestrogens to the Rat Uterine Estrogen Receptom, J Steroid Biochem Molec Biol, 64: 199-205, 1998.
SAG	60	MarteL C., Picard, S., Belanger, A., Labrie C., Labrie, F.: Prevention of bone loss by EM 800 and Raloxifene in the ovariectomized rat, J. Biochem. Mol. Biol., 74: 1-2: 45-46, 2000.

Examiner SAG	Date Considered 7/31/07

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.

APPLICANT'S ART CITATION (Use several sheets if necessary)	Application Not Yet Known	OFGS File No. P/1259-637 DIV
	Applicant Fernand Labrie	
	Filing Date Herewith	Group Art Unit --

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

SRP	61	Maudelonde, T., Brouillet, J.P., and Pujol, P., Antioestrogenes, SERM, tibolone: mecanisme d'action. Contracept Fertil Sex, 27, 620-624, 1999.
	62	Meites, J. (1980), Relation of the neuroendocrine system to the development and growth of experimental mammary tumors. J. Neural. Transmission, 48: 25-42.
	63	Melsen, F., Melsen, B., Mosekilde, L., Bergmann, S.(1978), Histomorphic analysis of normal bone from the iliac crest. Acta Pathol. Microbiol. Scand., 86: 70-81.
	64	Merchenthaler, I., Funkhouser, J.M., Carver, J.M., Lundeen, S.G., Ghosh, and K., Winneker, R.C., The effect of estrogens and antiestrogens in a rat model for hot flush. Maturitas, 30, 307-316, 1998.
	65	Meunier, J.P., Vignot, E., Garnero, P., Confavreux, E., Paris, E., Liu-Leage, S., Sarkar, S., Liu, T., Wong, M., and Draper, M.W., Treatment of postmenopausal women with osteoporosis or low bone density with raloxifene, Osteoporos Int, 10, 330-336, 1999.
	66	Mijatovic, V., van der Mooren, M.J., Stehouwer, C.D.A., Netelenbos, J.C., and Kenemans, Postmenopausal hormone replacement, risk estimators for coronary artery disease and cardiovascular protection., Gynecol Endocrinol, 13, 130-144, 1999.
	67	Morales, A.J., Nolan, A.J., Nelson, J.C., Yen, S.C. (1994), Effects of replacement dose of dehydroepiandrosterone in men and women of advancing age. J. Clin. Endocrinol. Metab., 78: 1360-1367.
	68	Nasr, A., and Breckwoldt, M., Estrogen replacement therapy and cardiovascular protection: lipid mechanisms are the tip of an iceberg, Gynecol Endocrinol, 12, 43-59, 1998.
	69	Need, A.G., Horowitz, M., Moris, H.A., Nordin, C. (1989), Effects of nandrolone decancate and antiresorptive therapy on vertebral density in osteoporotic postmenopausal women. Arch. Intern. Med., 149: 57-60.
	70	Nuttall, M.E., Bradbeer, J.N., Stroup, G.B., Nadeau, D.P., Hoffman, S.J., Zhao, H., Rehm, S., and Gowen, M., Idoxifene: A novel Selective Estrogen Receptor Modulator preventsbone loss and lowers cholesterol levels in ovariectomized rats and decreases uterine weight in intact rats., Endocrinology, 139(12), 5224-5234, 1998.
	71	Palkowitz et al., Discovery and synthesis of [6-hydroxy-3-[4-[2-(1 piperidinyl)ethoxy]phenoxy]-2-(4-hydroxyphenyl)]b enzo[b]thiophene: a novel, highly potent, selective estrogen receptor modulator. J Med Chem. 1997 May 9;40(10):1407-16.
	72	Parfitt, A.M. (1984), 1he cellular base of bone remodeling: the quantum concept reexamined in light of recent advances in the cell biology of bone. Calcified Tissue International, 36 Suppl. 1: S37-S45.
	73	Poulin, R., Baker, D., Labrie, F. (1988), Androgens inhibit basal and estrogen-induced cell proliferation in the ZR-75-1 human breast cancer cell line. Breast Cancer Res. Treatm., 12:213-225.
	74	Poulin, R., Labrie, F. (1986), Stimulation of cell proliferation and estrogenic response by adrenal C19-D5 steroids in the ZR-75-1 human breast cancer cell line. Cancer Res., 46: 4933-4937.
SRP	75	Preston Martin, S., Pike, M.C., Ross, R.K., Jones, P.A., Henderson, B.E., (1990), Increased cell division as a cause of human cancer. Cancer. Res., 50: 7415-21

Examiner SRP	Date Considered SRP 7/31/03

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.

APPLICANT'S ART CITATION (Use several sheets if necessary)	Application Not Yet Known	OFGS File No. P/1259-637
	Applicant Fernand Labrie	
	Filing Date Herewith	Group Art Unit --

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

SAD	76	Rosati et al., Discovery and preclinical pharmacology of a novel, potent, nonsteroidal estrogen receptor agonist/antagonist, CP-336156, a diaryltetrahydronaphthalene. J Med Chem. 1998 Jul 30;41(16):2928-31.
	77	Russell, J.C., Amy; R.M., Graham, S., Wenzel, L.M., Dolphin, P.J., (1993), Effect of castration on hyperlipidemic, insulin resistant JCR: LA-corpulent rats. Atherosclerosis, 100: 113-266.
	78	Russo, I.H., Medado, J., Russo, J. (1989), Endocrine influences on the mammary gland. Monographs on pathology of laboratory animals: integument and mammary glands, pp.252-266.
	79	Saarto, T., Blomqvist, C., Valimaki M., Makela, P., Sarna, S., Elomaa, I. (1997), Clodronate improves bone mineral density in post-menopausal breast cancer patients treated withadjuvant antiestrogens. Br. J. Cancer, Osteoporosis, 75: 602-605.
	80	Sato, M., Turner, C.H., Wang, T., Dee, A., Rowley, E., and Bryant, H.U.(1998) LY353381.HC1: a novel raloxifene analog with improved SERM potency and efficacy in vivo. J. Pharmacol. Exp. Ther. 287 (1), 1-7.
	81	Sherwin, B.B., Gelfand, M.M. (1984), Effects of parenteral administration of estrogen and androgen on plasma hormone levels and hot flushes in the surgical menopause. Am. J. Obstet. Gynecol., 148: 552-557.
	82	Sibonga, J.D., Evans, G.L., Hauck, E.R., Bell, N.H., Turner, R.T. (1996), Ovarian status influences the skeletal effects of tamoxifen in adult rats. Breast Cancer Res. Treatm., 41:71-79.
	83	Simard, J., Labrie, C., Belanger, A., Gauthier, S., Singh, S.M., Merand, Y., Labrie F.: Characterization of the effects of the novel non-steroidal antiestrogen EM-800 on basal and estrogen-induced proliferation of T-47D, AR-75-1 and MCF-7 human breast cancer cells in vitro. Int. J. Cancer, 73: 104-112, 1997.
	84	Simard, J., Sanchez, R., Poirier, D., Gauthier, S., Singh, S.M., Merand Y., Belanger, A., Labrie C., Labrie F.: Blockade of the stimulatory effect of estrogens, OH-Tamoxifen, OHToremifene, Droloxifene and Raloxifene on alkaline phosphatase activity by tneantiestrogen EM-800. Endocrinology, 138: 5605-5617, 1997.
	85	Sortino, M.A., Wise, P.M. (1989), Effects of age and long term ovariectomy on prolactin secretion, as assessed by the reverse hemolytic plaque assay. Endocrinology, 124: 90-96.
	86	Steingold, K.A., Laufer, L., Chetkowski, R.J., DeFazio, J.D., Matt, D.W., Meldrum, D.R., Judd, H .L.: Treatment of hot flashes with transdermal estradiol administration. J Clin Endocrinol Metab, 61: 627-32. 1985.
	87	Tang et al., Effect of Estrogen and Progesterone on the Development of Endometrial Hyperplasia in the Fischer Rat, Biol. Reprod. 31, 399-413, 1984.
	88	Vakamatsou, E. et al.: Calcified Tissue International, 37: 594-597, 1985.
	89	Wakeling, A.E. (1993), The Future of new pure antiestrogens in clinical breast cancer. Breast Cancer Res. Treat., 25: 1-9
SAD	90	Walsh, B.W., Schiff, I., Rosner, B., Greenberg, L., Ravoikar, V., Sacks, F.M. (1991), Effects of postmenopausal estrogen replacement on the concentrations and metabolism of plasma lipoproteins. New Engl. J. Med., 325: 1196-1204

Examiner SAD	Date Considered 7/31/03

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.

APPLICANT'S ART CITATION (Use several sheets if necessary)	Application Not Yet Known	OFGS File No. P/1259-637
	Applicant Fernand Labrie	
	Filing Date Herewith	Group Art Unit --

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

SAG	91	Weinstein, R.S., Hutson, M.S. (1987), Decreased trabecular width and increased trabecular spacing contribute to bone loss with aging. Bone, 8: 137-142.
	92	Willson, T.M., Norris, J.D., Wagner, B.L., Asplin, I., Baer, P., Brown, H.R., Jones, S.A.,Henke, B., Sauls, H., Wolfe, S., Morris, D.C., McDonnell, D.P. (1997), Dissection of the molecular mechanism of action of GW5638, a novel estrogen receptor ligand, provides insights into the role of estrogen receptor in bone. Endocrinology, 138: 3901-3911
	93	Wu, X., Glinn, M.A., Ostrowski, N.L., Su, Y., Ni, B., Cole, H.W., Bryant, H.U., and Paul, S.M., Raloxifene and estradiol benzoate both fully restore hippocampal choline acetyltransferase activity in ovariectomozed rats, Brain Research, 847, 98-104, 1999.
	94	Guidelines for preclinical and clinical evaluation of agents used in the prevention or treatment of postmenopausal osteoporosis, Division of Metabolism and Endocrine Drug Products, FDA, May 1994.
SAG	95	Minutes of the Endocrinology and Metabolism Drugs Advisory Committee, FDA, Thursday, Meeting # 68, November 20th 1997.

Examiner SAG	Date Considered 7/31/03

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.

APPLICANT'S ART CITATION

(Use several sheets if necessary)

Application	10/052,803	OFGS File No.	P/1259-637
Applicant	Fernand Labrie		
Filing Date	November 7, 2001	Group Art Unit	

U.S. PATENT DOCUMENTS

Examiner Initial	Document Number	Date	Name	Class	Sub-class	Filing Date if Appropriate
SAP	5 9 9 8 4 0 2	12/1999	Miller et al.	514	212	

FOREIGN PATENT DOCUMENTS

	Document Number	Date	Country	Class	Sub-class	Translation Yes	Translation No

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

Examiner SAP Date Considered 7/31/03

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.

APPLICANT'S ART CITATION

(Use several sheets if necessary)

Application 10/052,803	OFGS File No. P/1259-637
Applicant Fernand LABRIE	
Filing Date November 7, 2001	Group Art Unit 1617

U.S. PATENT DOCUMENTS

Examiner Initial	Document Number	Date MM-YYYY	Name	Class	Sub-class	Filing Date If Appropriate
SEQ	US-5,770,226	06-1998	Hughes, Jr., et al.	424	464	July 10, 1996
SEQ	US-5,780,460	07-1998	Labrie	514	178	Jun. 7, 1995
	US-					
	US-					
	US-					
	US-					
	US-					
	US-					
	US-					
	US-					

FOREIGN PATENT DOCUMENTS

	Document Number	Date MM-YYYY	Country	Class	Sub-class	Translation Yes	Translation No

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

Examiner SEQ

Date Considered 7/31/03

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.